Rubraca
- Product NDC
- 82154-0783
- 11-digit product format
- 821540783
- Labeler code
- 82154
- Product ID
- 82154-0783_473a8026-e822-2a9e-e063-6294a90a5c06
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- rucaparib
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- pharmaand GmbH
- Application
- NDA209115
- Marketing category
- NDA
- Marketing start
- 2016-12-19
- Substance
- RUCAPARIB CAMSYLATE
- Active strength
- 200 mg/1
- Pharmacologic classes
- Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N209115-001 | RUBRACA | RUCAPARIB CAMSYLATE | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | |
| N209115-002 | RUBRACA | RUCAPARIB CAMSYLATE | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | |
| N209115-003 | RUBRACA | RUCAPARIB CAMSYLATE | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N209115-001 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-001 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-001 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-001 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-001 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-001 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-001 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | |
| N209115-001 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-001 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-001 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | |
| N209115-001 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | |
| N209115-001 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | |
| N209115-001 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | |
| N209115-001 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | |
| N209115-001 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | |
| N209115-002 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-002 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-002 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-002 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-002 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-002 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-002 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | |
| N209115-002 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-002 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-002 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | |
| N209115-002 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | |
| N209115-002 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | |
| N209115-002 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | |
| N209115-002 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | |
| N209115-002 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | |
| N209115-003 | 8071579 | 2027-08-12 | U-2012 | 2017-05-09 | |
| N209115-003 | 8071579 | 2027-08-12 | U-2273 | 2017-05-09 | |
| N209115-003 | 8071579 | 2027-08-12 | U-2830 | 2017-05-09 | |
| N209115-003 | 8143241 | 2027-08-12 | U-2012 | 2017-05-09 | |
| N209115-003 | 8143241 | 2027-08-12 | U-2273 | 2017-05-09 | |
| N209115-003 | 8143241 | 2027-08-12 | U-2830 | 2017-05-09 | |
| N209115-003 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | |
| N209115-003 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2017-05-09 | |
| N209115-003 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2017-05-09 | |
| N209115-003 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | |
| N209115-003 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | |
| N209115-003 | 8859562 | 2031-08-04 | U-2012 | 2017-05-09 | |
| N209115-003 | 8859562 | 2031-08-04 | U-2273 | 2017-05-09 | |
| N209115-003 | 8859562 | 2031-08-04 | U-2830 | 2017-05-09 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | |
| N209115-003 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 |
Orange Book exclusivity#
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| N209115-001 | I-982 | 2028-12-17 |
| N209115-002 | I-982 | 2028-12-17 |
| N209115-003 | I-982 | 2028-12-17 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-003 | 8071579 | 2027-08-12 | U-2012 | 2017-05-09 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N209115-003 | 8071579 | 2027-08-12 | U-2273 | 2017-05-09 | a50c72e98297… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N209115-001 | I-982 | 2028-12-17 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N209115-002 | I-982 | 2028-12-17 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N209115-003 | I-982 | 2028-12-17 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Rubraca | RUCAPARIB | pharmaand GmbH | 0295d202-1cfe-7659-e063-6294a90a476e | 2025-12-31 | Warnings, Adverse reactions | 209115 NDA209115 82154-0783 |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Rubraca
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| RUCAPARIB CAMSYLATE | 200 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 41AX9SJ8KO | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 0295d202-1cfe-7659-e063-6294a90a476e | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 594e2c86-3079-4e6e-96c9-48f7a8afc78d | Product name | 1 | 20230718 |
| f430e54b-e9d6-4b78-bc11-c25cef55f87c | Product name | 1 | 20170302 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 82154-0783-1 | Rubraca | 60 in 1 BOTTLE | TABLET, FILM COATED | 60 | 19 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 82154-0783-1 | EA - Each | 82154-0783 | 7b1894ab-41bd-4d54-a861-fe4605c5fb61 | 1 | 2025-01-14 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 82154-0783 | RUBRACA (RUCAPARIB) TABLET, FILM COATED [PHARMAAND GMBH] | 18 | Current NDC, 1 package rows | 20250130_0295d202-1cfe-7659-e063-6294a90a476e.zip |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 1862595 | Rubraca 200 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921589 | Rubraca 250 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862590 | Rubraca 300 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862593 | rucaparib 200 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921587 | rucaparib 250 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862584 | rucaparib 300 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862595 | rucaparib 200 MG Oral Tablet [Rubraca] | SBD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921589 | rucaparib 250 MG Oral Tablet [Rubraca] | SBD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862590 | rucaparib 300 MG Oral Tablet [Rubraca] | SBD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862593 | rucaparib 200 MG Oral Tablet | SCD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921587 | rucaparib 250 MG Oral Tablet | SCD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862584 | rucaparib 300 MG Oral Tablet | SCD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862595 | Rubraca (as rucaparib camisylate) 200 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921589 | Rubraca (as rucaparib camisylate) 250 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862590 | Rubraca (as rucaparib camisylate) 300 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862595 | Rubraca 200 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921589 | Rubraca 250 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862590 | Rubraca 300 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921587 | rucaparib (as rucaparib camisylate) 250 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862593 | rucaparib (as rucaparib camsylate) 200 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862584 | rucaparib (as rucaparib camsylate) 300 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 82154-0783-1 | 82154078301 | 60 TABLET, FILM COATED in 1 BOTTLE (82154-0783-1) | 2016-12-19 | No | No | Current |